MedTrace Logo

Phase II Trial for the Treatment of Relapsed Osteosarcoma

NCT02718482 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-05-13

No results posted yet for this study

Summary

Phase II randomized study for the comparison of the Gemcitabine plus Docetaxel and the Ifosfamide treatment of patients with relapsed osteosarcoma

Conditions

Interventions

DRUG

Gemcitabine and Docetaxel

Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle

DRUG

Ifosfamide

Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle

Sponsors & Collaborators

  • Italian Sarcoma Group

    lead NETWORK

Principal Investigators

  • Stefano Ferrari, MD · Istituto Ortopedico Rizzoli

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-06
Primary Completion
2019-01-07
Completion
2019-01-07

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02718482 on ClinicalTrials.gov